The Atorvastatin Goal Achievement Across Risk Levels: (ATGOAL) study in Thailand.
Article
Dans Anglais
| IMSEAR
| ID: sea-39430
ABSTRACT
OBJECTIVE:
To evaluate the efficacy and safety of atorvastatin at the starting doses of 10, 20, 40 mg and evaluate the effectiveness of 1 step titrate up regimen. MATERIAL ANDMETHOD:
Two hundred and forty two subjects with dyslipidemia were enrolled and assigned the appropriate dose in relation to their individual cardiovascular risk status and baseline LDL-C levels. If the NCEP targets were not achieved, the doses were titrated up at week 4 and the primary efficacy was evaluated at week 8.RESULTS:
A majority of subjects (88.8%) achieved their LDL-C goals at week 8. Almost all of the subject's LDL-C levels reached their goals by week 2 and 4 (81.6% and 87.1%, respectively). Only 10.7% (n = 25) required the sole titration. Each dose provided significant decreases in LDL-C (average -46.4%). Only 36 subjects experienced treatment related adverse events, the majority of these were in the high-risk group (n = 22) with only one subject registering a serious adverse event.CONCLUSION:
Atorvastatin is effective and safe for Thai patients with dyslipidemia. The appropriate starting dose has contributed in the achievement of cholesterol reduction.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Pyrroles
/
Sujet âgé de 80 ans ou plus
/
Sujet âgé
/
Femelle
/
Humains
/
Mâle
/
Adolescent
/
Résultat thérapeutique
/
Appréciation des risques
/
Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase
Type d'étude:
Etude d'étiologie
/
Facteurs de risque
Limites du sujet:
Aged80
langue:
Anglais
Année:
2007
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS